Articles

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Department of Hematology, CLCC Centre Léon Bérard, Lyon, France
Istanbul Medical Faculty, Istanbul University, Turkey
Department of Internal Medicine III, Ludwig-Maximilians University of Munich, Germany
Department of Hematology, Ankara University School of Medicine, Turkey
Department of Hematology, Uddevalla Hospital, Sweden
Department of Hematology, Centre Hospitalier du Mans, Le Mans, France
Hematology Department, Aziza Othmana University Hospital, Tunis, Tunisia
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hematology Service, Hospital de Santa Maria, Lisbon, Portugal
Department of Oncology, Oxford University Hospitals, UK
Department of Hematology, Erciyes University Medical School, Kayseri, Turkey
Department of Internal Medicine, Peijas Hospital, Vantaa, Finland
Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Medical Affairs, Roche Pharma AG, Grenzach-Wyhlen, Germany
Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Clinical Hematology, AP-HP Hôpital Pitié-Salpêtrière, UPMC University, Paris, France
Vol. 103 No. 4 (2018): April, 2018 https://doi.org/10.3324/haematol.2017.170480